Unlocking SINGLE
CELL BIOLOGY
Beyond ctDNA
An integrated platform combining live single-cell CTC multi-omics with matched ctDNA—from a single blood draw.
Kaplan–Meier Overall Survival By Mutation Signature
OncoIncytes® detects bypass mutations in single circulating tumor cells (sCTC) at baseline—capturing private, sub-clonal variants invisible to ctDNA, enabling earlier resistance profiling.
Patients with bypass pathway mutations have dramatically worse overall survival, indicating a 4× higher risk of death compared to hotspot-only carriers.
Key Finding: Baseline detection of EGFR bypass pathway mutations in sCTC predicts early TKI resistance and significantly reduced overall survival — outperforming ctDNA alone.
Clinical Rationale & Evidence
TKI therapy is the standard of care for EGFRm NSCLC, yet many patients develop acquired resistance—often driven by EGFR bypass pathway mutations missed by conventional ctDNA testing.
Key Finding: Baseline detection of EGFR bypass pathway mutations in sCTC predicts early TKI resistance and significantly reduced overall survival — outperforming ctDNA alone.
Discover OncoIncytes®
Transforming Precision Oncology
Learn more about how OncoIncytes® is unlocking the power of true single-cell multi-omics to guide better clinical decisions.
© 2026 1Cell.Ai. All rights reserved.